Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.

Glewis, Sarah; Lingaratnam, Senthil; Krishnasamy, Mei; H Martin, Jennifer; Tie, Jeanne; Alexander, Marliese; Michael, Michael

Glewis, Sarah; Lingaratnam, Senthil; Krishnasamy, Mei; H Martin, Jennifer; Tie, Jeanne; Alexander, Marliese; Michael, Michael.

Afiliação

Glewis S; Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia.
Lingaratnam S; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Krishnasamy M; Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia.
H Martin J; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Tie J; Academic Nursing Unit, Peter MacCallum Cancer Centre, Melbourne, Australia.
Alexander M; VCCC Alliance, Parkville, Australia.
Michael M; School of Medicine and Public Health, University of Newcastle, New South Wales, Australia.

J Oncol Pharm Pract ; 30(1): 30-37, 2024 Jan.

Article em En | MEDLINE | ID: mdl-37021580

Assuntos

Farmacêuticos; Farmacogenética; Humanos; Irinotecano/uso terapêutico; Di-Hidrouracila Desidrogenase (NADP)/genética; Antimetabólitos; Oncologia

Palavras-chave

DPYD; Fluoropyrimidine; UGT1A1; irinotecan; pharmacogenetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacêuticos / Farmacogenética Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google